147080-46-4

Upstream product

• 29147-88-4 4-(heptyloxy)benzonitrile 
• 123732-04-7 4-n-heptyloxybromobenzene 

Downstream Products

• 171363-74-9 3-(4-n-Heptyloxyphenyl)-5-(4-nitrophenyl)-1,2,4-oxadiazole 
• 1443791-84-1 (S)-methyl 2-(4-(tert-butyl)benzamido)-3-(4-(((4-(heptyloxy)benzimidamido)oxy)carbonyl)phenyl)propanoate 
• 1443791-83-0 (S)-methyl 2-(4-(tert-butyl)benzamido)-3-(4-(3-(4-(heptyloxy)phenyl)-1,2,4-oxadiazol-5-yl)phenyl)propanoate 
• 1443788-24-6 (S)-2-(4-(tert-butyl)benzamido)-3-(4-(3-(4-(heptyloxy)phenyl)-1,2,4-oxadiazol-5-yl)phenyl)propanoic acid 

Relevant academic research and scientific papers

GLP-1 RECEPTOR MODULATORS

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "^^^^" represents either or both the R and S form of the compound) (I) where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

NOVEL GLP-1 RECEPTOR MODULATORS

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "()" represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

NOVEL GLP-1 RECEPTOR MODULATORS

The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where"﹋" represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.

The Synthesis and Liquid Crystal Properties of Some Series Homologues of 1,2,4-Oxadiazole Derivatives

Homologues series of some derivatives of 3,5-(4-substituted phenyl)-1,2,4-oxydiazole were synthesized and their phase behavior studied.Introduction of the pentagonal heteroaromatic ring leads to significant changes in mesomorphic behavior in comparison with analogous compounds containing the phenyl ring.The synthesised compounds exhibit smectic and nematic phases. - Keywords: 1,2,4-oxadiazole, nematic and smectic liquid crystals